Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
▼
$0.04
N/A26.97100 shsN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$12.82
-2.3%		$12.01
$9.77
▼
$18.30
$2.29B0.24101,001 shs82,741 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ERGO
Entia Biosciences
0.00%0.00%+300.00%+33.33%+700.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-2.29%-9.01%+4.65%+16.97%-18.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
▼
$0.04
N/A26.97100 shsN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$12.82
-2.3%		$12.01
$9.77
▼
$18.30
$2.29B0.24101,001 shs82,741 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ERGO
Entia Biosciences
0.00%0.00%+300.00%+33.33%+700.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-2.29%-9.01%+4.65%+16.97%-18.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ERGO
Entia Biosciences
0.00
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.43
Hold$14.8715.96% Upside

Current Analyst Ratings Breakdown

Latest AMYT, HCM, VEC, and ERGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
9/3/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Daiwa Securities Group Inc. logo
Daiwa Securities Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
7/31/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D)
7/23/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$16.00 ➝ $14.00
7/17/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/7/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $17.00
6/29/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M4.08$2.63 per share4.87$7.17 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A58.27N/AN/AN/AN/AN/A

Latest AMYT, HCM, VEC, and ERGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026H1 2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$0.1450$0.05-$0.0950$0.05$304.16 million$139.14 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ERGO
Entia Biosciences
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50

Institutional Ownership

CompanyInstitutional Ownership
ERGO
Entia Biosciences
N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
ERGO
Entia Biosciences
28.30%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionNot Optionable

Recent News About These Companies

HSBC Upgrades HUTCHMED (NASDAQ:HCM) to "Buy"
September 10 at 1:30 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013742
HUTCHMED (NASDAQ:HCM) Upgraded by HSBC to "Buy" Rating
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hutchmed-nasdaq-hcm-upgraded-by-hsbc-to-buy-rating-2026-09-08/
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow
September 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943635-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Daiwa Securities Group
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004807
HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at Daiwa Securities Group
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hutchmed-nasdaq-hcm-rating-increased-to-buy-at-daiwa-securities-group-2026-09-03/
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-hutchmed-lands-gsk-deal-worth-up-to-13b-for-kras-egfr-cancer-therapy-2026-09-03/
HUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-gap-up-whats-next-2026-09-03/
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942785-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688056/hutchmed-licenses-hmpl-a830-to-gsk-in-1-295-bln-deal-for-cancer-therapy-stock-up-14.aspx
Hutchmed strikes licensing agreement with GSK
September 3, 2026  |  thepharmaletter.comT
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098046?snapi
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034?snapi
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
September 3, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/hutchmed-china-signs-licensing-deal-with-gsk-experimental-solid-tumour-drug-2026-09-03/
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355629/0/en/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-therapy.html
HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - Here's What Happened
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-sees-large-volume-increase-heres-what-happened-2026-09-02/
AstraZeneca, Hutchmed succeed in late-stage lung cancer trial for Orpathys, Tagrisso combo
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/astrazeneca-hutchmed-succeed-in-late-stage-lung-cancer-trial-for-orpathys-tagrisso-combo/ar-AA2bmfAS
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving Average - Here's Why
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-pass-above-fifty-day-moving-average-heres-why-2026-09-01/
HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3686757/hutchmed-reports-positive-phase-3-sanovo-data-for-orpathys-plus-tagrisso-in-egfr-mutant-nsclc.aspx
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing ...
August 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/hutchmed-announces-sanovo-trial-demonstrated-significant-progression-free-survival-benefit-of-orpathys-plus-tagrisso-in-treatment-na-ve-patients-with-met-overexpressing-egfr-mutated-lung-cancer-1036505134
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
August 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353003/0/en/hutchmed-announces-sanovo-trial-demonstrated-significant-progression-free-survival-benefit-of-orpathys-plus-tagrisso-in-treatment-na%c3%afve-patients-with-met-overexpressing-egfr-mutate.html

Media Sentiment Over Time

Entia Biosciences OTCMKTS:ERGO

$0.0008 0.00 (0.00%)
As of 09/11/2026

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$12.82 -0.30 (-2.29%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$12.82 +0.00 (+0.04%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas